TauRx To File First Tau-Targeting Drug For Alzheimer’s Following Additional Pivotal Data
Executive Summary
After previous late-stage setbacks, the Singaporean firm TauRx’s tau aggregation inhibitor asset has succeeded in a pivotal Alzheimer’s disease trial with promising new biomarker data sparking plans for regulatory filings in the US and UK.